Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $8.75 Consensus Target Price from Brokerages

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) have received an average rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $8.75.

CRDF has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a report on Monday, May 18th. HC Wainwright lowered shares of Cardiff Oncology from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. TD Cowen lowered shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a report on Monday, June 1st. Wall Street Zen lowered shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Piper Sandler lowered their target price on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th.

Institutional Investors Weigh In On Cardiff Oncology

Institutional investors have recently added to or reduced their stakes in the company. Brooklyn Investment Group bought a new stake in Cardiff Oncology in the 3rd quarter worth about $26,000. Capital Advisors Wealth Management LLC bought a new stake in Cardiff Oncology in the 4th quarter worth about $30,000. Tamar Securities LLC bought a new stake in Cardiff Oncology in the 4th quarter worth about $32,000. R Squared Ltd bought a new stake in Cardiff Oncology in the 4th quarter worth about $36,000. Finally, Engineers Gate Manager LP bought a new stake in Cardiff Oncology in the 2nd quarter worth about $43,000. 16.29% of the stock is owned by institutional investors.

Cardiff Oncology Price Performance

CRDF opened at $1.26 on Wednesday. Cardiff Oncology has a fifty-two week low of $1.26 and a fifty-two week high of $4.56. The firm has a market capitalization of $86.15 million, a PE ratio of -1.88 and a beta of 1.36. The company’s 50-day moving average is $1.65 and its 200 day moving average is $1.99.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Cardiff Oncology had a negative return on equity of 95.51% and a negative net margin of 8,527.43%.The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.09 million. As a group, analysts expect that Cardiff Oncology will post -0.66 EPS for the current year.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.